VERONA PHARMA PLC - AMERICAN DEPOSITARY SHARES

Verona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate Update

19 يوليو 2023 23:00:00 بحسب Nasdaq GlobeNewswire

Verona Pharma Announces Publication of Phase 3 ENHANCE Data in the American Journal of Respiratory and Critical Care Medicine

27 يونيو 2023 23:00:00 بحسب Nasdaq GlobeNewswire

Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD

26 يونيو 2023 23:00:00 بحسب Nasdaq GlobeNewswire

Verona Pharma to Present at Jefferies Healthcare Conference

23 مايو 2023 23:00:00 بحسب Nasdaq GlobeNewswire

Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

08 مايو 2023 23:00:00 بحسب Nasdaq GlobeNewswire

Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023

01 مايو 2023 23:00:00 بحسب Nasdaq GlobeNewswire

Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update

24 أبريل 2023 23:00:00 بحسب Nasdaq GlobeNewswire

Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD

09 أبريل 2023 23:00:00 بحسب Nasdaq GlobeNewswire

Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

06 مارس 2023 23:00:00 بحسب Nasdaq GlobeNewswire

Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update

20 فبراير 2023 23:00:00 بحسب Nasdaq GlobeNewswire

Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD

19 ديسمبر 2022 23:00:00 بحسب Nasdaq GlobeNewswire

Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-1 Trial of Nebulized Ensifentrine for COPD

19 ديسمبر 2022 13:01:00 بحسب Nasdaq GlobeNewswire

Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update

08 نوفمبر 2022 23:00:00 بحسب Nasdaq GlobeNewswire

Verona Pharma Announces November 2022 Investor Conference Participation

02 نوفمبر 2022 00:00:00 بحسب Nasdaq GlobeNewswire

Verona Pharma to Report Third Quarter 2022 Financial Results and Provide Corporate Update

25 أكتوبر 2022 23:00:00 بحسب Nasdaq GlobeNewswire

Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance

16 أكتوبر 2022 23:00:00 بحسب Nasdaq GlobeNewswire

Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD

13 أكتوبر 2022 23:00:00 بحسب Nasdaq GlobeNewswire

Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference

28 أغسطس 2022 23:00:00 بحسب Nasdaq GlobeNewswire

Verona Pharma strengthens commercialization leadership team

23 أغسطس 2022 23:00:00 بحسب Nasdaq GlobeNewswire

Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China

18 أغسطس 2022 23:46:07 بحسب Nasdaq GlobeNewswire